Special Issue

A Personalized Medicine Approach to the Diagnosis and Management of Autism Spectrum Disorder: Beyond Genetic Syndromes

Message from the Guest Editors

Autism spectrum disorder (ASD) now affects more than 2% of children, and its prevalence continues to grow. Currently, there is no curative treatment and current therapies provide suboptimal habilitation in many individuals that are affected, leading to a new framing of ASD as a lifelong disorder for many rather than simply a disorder isolated to childhood. A majority of research on ASD concentrates on identifying the genetic syndrome, but there is a new understanding that the etiology of ASD is very complex and probably driven by genetic variations and vulnerabilities interacting with environmental exposures and triggers. Our two previous Special Issues have provided insight into applying personalized medicine to improve the diagnosis and detection of pathophysiological processes and predict treatment response in individuals with ASD. This year, we focus on the emerging understanding of the role of environmental factors, their contribution to genetic variants and vulnerabilities, and their interaction with the environment.

Guest Editors

Prof. Dr. Richard E. Frye

Dr. Richard G. Boles

Dr. Daniel Rossignol

Dr. Shannon Rose

Deadline for manuscript submissions

closed (30 April 2024)

Journal of Personalized Medicine

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).